Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medlive Technology CoFRA:1JZ +2.93%90 PB Ratio is 1.05 as of Aug. 03, 2026, which is 23% below its 10-year median of 1.36. GuruFocus rates FRA:1JZ with a GF Score™ of 90/100 and a GF Value™ of €1.61. The stock has 5 warning signs investors should review. Among 607 Healthcare Providers & Services companies, Medlive Technology Co ranks better than 76.28% on this metric.
The historical rank and industry rank for Medlive Technology Co's PB Ratio or its related term are showing as below:
FRA:1JZ'
s PB Ratio Range Over the Past 10 Years
Min: 0.86 Med: 1.36 Max: 172.88
Current: 1.07
During the past 8 years, Medlive Technology Co's highest PB Ratio was 172.88. The lowest was 0.86. And the median was 1.36.
FRA:1JZ's PB Ratio is ranked better than 76.28% of 607
companies
in the Healthcare Providers & Services industry
Industry Median: 2.05
vs FRA:1JZ: 1.07
During the past 12 months, Medlive Technology Co's average Book Value Per Share Growth Rate was 4.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 2.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 61.50% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Medlive Technology Co was 388.90% per year. The lowest was 1.00% per year. And the median was 198.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Medlive Technology Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medlive Technology Co PB Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Medlive Technology Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Medlive Technology Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Medlive Technology Co (FRA:1JZ) has a PB Ratio of 1.05 as of Aug. 03, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Medlive Technology Co and its competitors. This is 23% below median its historical median of 1.36. Over the past decade, Medlive Technology Co's PB Ratio has ranged from 0.86 to 172.88. According to the industry distribution chart, Medlive Technology Co ranks #144 out of 607 companies in the Healthcare Providers & Services industry, placing it in the top 23.7%.
Is Medlive Technology Co's PB Ratio too high?
Medlive Technology Co's current PB Ratio of 1.05 is 23% below median its 10-year median of 1.36. Over the past 10 years, this metric has ranged from a low of 0.86 to a high of 172.88. The Healthcare Providers & Services industry median PB Ratio is 2.05. Medlive Technology Co's value of 1.05 is 48.8% below this industry median. Based on the distribution chart, Medlive Technology Co ranks #144 out of 607 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Medlive Technology Co has a GF Score™ of 90/100, reflecting its overall financial health beyond just this single metric.
How does Medlive Technology Co's PB Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Medlive Technology Co ranks #144 out of 607 companies for PB Ratio. This places Medlive Technology Co in the top 24% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.05. Medlive Technology Co's value of 1.05 is 48.8% below this benchmark. Historically, Medlive Technology Co's own PB Ratio has ranged from 0.86 to 172.88 over the past decade. While the company's 10-year median is 1.36 vs. the industry median of 2.05, Medlive Technology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Healthcare Providers & Services company?
The median PB Ratio among Healthcare Providers & Services companies is 2.05, based on 607 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medlive Technology Co's current PB Ratio of 1.05 is 48.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Medlive Technology Co and its competitors. For the Healthcare Providers & Services industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medlive Technology Co's current PB Ratio is 1.05, which is 23% below median its own 10-year median of 1.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medlive Technology Co stock overvalued right now?
Medlive Technology Co (FRA:1JZ) has a current PB Ratio of 1.05. The stock's GF Value™ is €1.61, compared to a current price of €0.84 — trading 47.6% below its estimated fair value. The current PB Ratio is 1.05, which is 23% below median its 10-year median of 1.36 and 48.8% below the Healthcare Providers & Services industry median of 2.05. Medlive Technology Co's overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Medlive Technology Co (FRA:1JZ), the current PB Ratio is 1.05 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medlive Technology Co (FRA:1JZ) Overvalued in 2026?
Based on GuruFocus' analysis, Medlive Technology Co stock appears to be undervalued.
The current stock price of €0.84 is trading 47.6% below its estimated GF Value™ of €1.61.
Key valuation signals for FRA:1JZ:
PB Ratio: 1.05 (23% below median its 10-year median of 1.36)
GF Value™: €1.61 vs. price of €0.84 (47.6% below fair value)
Industry Position: 48.8% below the Healthcare Providers & Services median (#144 of 607)
No single metric tells the full story. See the FRA:1JZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medlive Technology Co Ltd is a digital healthcare marketing company that produces customized content for pharmaceutical and medical device firms. The company developed into a professional provider of medical information services and precision digital marketing services. Its platform also provides medical content consisting of third-party research, informal discussions, and medical news articles. The company also operates a minor internet hospital and a SaaS solution that helps with medical conferences and clinical research.
90GF Score
Get the complete analysis for FRA:1JZ
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1JZ has been successfully added to your 
